In August 2018, the Centers for Medicare and Medicaid Services (CMS) announced it would permit Medicare Advantage plans to use step therapy for Part B drugs, with a lookback period of just 108 days.1 On May 16, 2019, however, the CMS issued a final rule that extends the lookback period for Part B therapies to 365…
Search results for: health insurance
British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars
TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…

Wisconsin Rheumatologist Visits Rheumatology Training Program in Nepal
A Milwaukee rheumatologist delivered lectures, participated in Grand Rounds and consulted on rheumatology treatment strategies during his visit this winter to the Patan Academy of Health Sciences (PAHS), Nepal. Paul Halverson, MD, affiliated with Froedtert Hospital and the Medical College of Wisconsin, says the several days he spent in Patan, Nepal, adjacent to Kathmandu and…

Prevent Osteoporotic Fractures with a Fracture Liaison Service
Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…

What Pharmacists Want Rheumatologists to Know
Involving pharmacists in the management of chronic diseases benefits patients, says Wendy Ramey, BSPharm, RPh, CSP, a clinical pharmacy specialist in rheumatology at the University of Kentucky, Lexington. She knows this personally. As someone with rheumatoid arthritis (RA), Ms. Ramey knows pharmacists can play an important role in patient education and encouraging adherence to medications….

Employment Agreement Considerations for a New Practitioner
You are a new practitioner, ready to begin your first job, one for which you’ve been preparing for years. Your prospective employer gives you an agreement that outlines your compensation, scope of work, requirements and benefits. You are eager to start your new assignment, and you want to sign this document quickly to make your…

Rheumatology Drugs at a Glance, Part 2: Psoriasis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…
ACR/ARP Members Educate Lawmakers
Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May, per the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, researchers, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents. The two-day conference, which featured the…
ACR Leaders to Meet with Members of Congress
On May 16, ACR and ARP leaders serving on the Board of Directors, Affiliate Society Council, Government Affairs Committee, Committee on Rheumatologic Care, RheumPAC and Insurance Subcommittee will go to Capitol Hill to advocate on behalf of the College’s membership and our patients. The group represents 31 states and the District of Columbia, and will…
Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors
Over the past decade, physicians, patients and policy makers have expressed increasing concern about the high frequency of opioids being prescribed and the association between opioid use and poor outcomes. Rates of opioid prescriptions in the general population rose considerably from the 1990s through 2010, with a plateau in the early 2010s. In 2015, 38%…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 115
- Next Page »